Trimel Pharmaceuticals Corp. (TRLPF) Upgraded at ValuEngine

Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Trimel Pharmaceuticals Corp. (OTCMKTS TRLPF) opened at 0.0934 on Friday. Trimel Pharmaceuticals Corp. has a 52-week low of $0.07 and a 52-week high of $0.20. The company has a 50 day moving average price of $0.09 and a 200-day moving average price of $0.09. The firm has a market cap of $19.91 million, a price-to-earnings ratio of 9.3400 and a beta of 1.38.

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/08/12/trimel-pharmaceuticals-corp-trlpf-upgraded-at-valuengine.html.

Trimel Pharmaceuticals Corp. Company Profile

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.

What are top analysts saying about Trimel Pharmaceuticals Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trimel Pharmaceuticals Corp. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit